Last reviewed · How we verify
Vandetanib maintenance
Vandetanib maintenance is a Small molecule drug developed by PrECOG, LLC.. It is currently in Phase 2 development. Also known as: ZD6474.
Vandetanib is a medication that has been studied in clinical trials for various conditions, including non-small cell lung cancer (NSCLC) and metastatic breast cancer. It is a tyrosine kinase inhibitor, according to ChEMBL, which suggests that it works by blocking certain enzymes involved in cell growth and division.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vandetanib maintenance |
|---|---|
| Also known as | ZD6474 |
| Sponsor | PrECOG, LLC. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (PHASE2)
- Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors (PHASE1, PHASE2)
- Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer (PHASE2)
- Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vandetanib maintenance CI brief — competitive landscape report
- Vandetanib maintenance updates RSS · CI watch RSS
- PrECOG, LLC. portfolio CI
Frequently asked questions about Vandetanib maintenance
What is Vandetanib maintenance?
Who makes Vandetanib maintenance?
Is Vandetanib maintenance also known as anything else?
What development phase is Vandetanib maintenance in?
Related
- Manufacturer: PrECOG, LLC. — full pipeline
- Also known as: ZD6474
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing